Cambridge RNA Technologies

Safer, durable gene therapy - RNA that persists weeks, not days

  • Biotech
Therapeutics

Member

Active

Status

2025

Founded

Development stage

  • EngBio3
    Accelerate

Cambridge RNA Technologies is developing long-term RNAs (ltRNAs) - engineered RNA molecules that persist for weeks or months rather than hours. By combining the safety of RNA with durability previously only achievable through genome modification, ltRNAs enable durable therapeutic gene expression for protein replacement, immune cell engineering, and regenerative medicine without the risks of permanent genomic changes.

Founding team

Key contacts